Bifidobacterium

Last updated

Bifidobacterium
Bifidobacterium adolescentis Gram.jpg
Bifidobacterium adolescentis
Scientific classification OOjs UI icon edit-ltr.svg
Domain: Bacteria
Phylum: Actinomycetota
Class: Actinomycetia
Order: Bifidobacteriales
Family: Bifidobacteriaceae
Genus: Bifidobacterium
Orla-Jensen 1924 (Approved Lists 1980) [1]
Type species
Bifidobacterium bifidum
(Tissier 1900) Orla-Jensen 1924 (Approved Lists 1980)
Species

See text.

Bifidobacterium is a genus of gram-positive, nonmotile, often branched anaerobic bacteria. They are ubiquitous inhabitants of the gastrointestinal tract [2] [3] though strains have been isolated from the vagina [4] and mouth ( B. dentium ) of mammals, including humans. Bifidobacteria are one of the major genera of bacteria that make up the gastrointestinal tract microbiota in mammals. Some bifidobacteria are used as probiotics.

Contents

Before the 1960s, Bifidobacterium species were collectively referred to as Lactobacillus bifidus.

History

Some of the Bifidobacterium animalis bacteria found in a sample of Activia yogurt:  The numbered ticks on the scale are 10 micrometres apart. 20101210 013757 BifidobacteriumAnimalis.jpg
Some of the Bifidobacterium animalis bacteria found in a sample of Activia yogurt:  The numbered ticks on the scale are 10 micrometres apart.

In 1899, Henri Tissier, a French pediatrician at the Pasteur Institute in Paris, isolated a bacterium characterised by a Y-shaped morphology ("bifid") in the intestinal microbiota of breast-fed infants and named it "bifidus". [5] In 1907, Élie Metchnikoff, deputy director at the Pasteur Institute, propounded the theory that lactic acid bacteria are beneficial to human health. [5] Metchnikoff observed that the longevity of Bulgarians was the result of their consumption of fermented milk products. [6] Metchnikoff also suggested that "oral administration of cultures of fermentative bacteria would implant the beneficial bacteria in the intestinal tract". [7]

Metabolism

The genus Bifidobacterium possesses a unique fructose-6-phosphate phosphoketolase pathway employed to ferment carbohydrates.[ citation needed ]

Much metabolic research on bifidobacteria has focused on oligosaccharide metabolism, as these carbohydrates are available in their otherwise nutrient-limited habitats. Infant-associated bifidobacterial phylotypes appear to have evolved the ability to ferment milk oligosaccharides, whereas adult-associated species use plant oligosaccharides, consistent with what they encounter in their respective environments. As breast-fed infants often harbor bifidobacteria-dominated gut consortia, numerous applications attempt to mimic the bifidogenic properties of milk oligosaccharides. These are broadly classified as plant-derived fructooligosaccharides or dairy-derived galactooligosaccharides, which are differentially metabolized and distinct from milk oligosaccharide catabolism. [3]

Response to oxygen

The sensitivity of members of the genus Bifidobacterium to O2 generally limits probiotic activity to anaerobic habitats. Recent research has reported that some Bifidobacterium strains exhibit various types of oxic growth. Low concentrations of O2 and CO2 can have a stimulatory effect on the growth of these Bifidobacterium strains. Based on the growth profiles under different O2 concentrations, the Bifidobacterium species were classified into four classes: O2-hypersensitive, O2-sensitive, O2-tolerant, and microaerophilic. The primary factor responsible for aerobic growth inhibition is proposed to be the production of hydrogen peroxide (H2O2) in the growth medium. A H2O2-forming NADH oxidase was purified from O2-sensitive Bifidobacterium bifidum and was identified as a b-type dihydroorotate dehydrogenase. The kinetic parameters suggested that the enzyme could be involved in H2O2 production in highly aerated environments. [8]

Genomes

Members of the genus Bifidobacterium have genome sizes ranging from 1.73 (Bifidobacterium indicum) to 3.25 Mb (Bifidobacterium biavatii), corresponding to 1,352 and 2,557 predicted protein-encoding open reading frames, respectively. [9]

Functional classification of Bifidobacterium genes, including the pan-genome of this genus, revealed that 13.7% of the identified bifidobacterial genes encode enzymes involved in carbohydrate metabolism. [9]

Clinical uses

Adding Bifidobacterium as a probiotic to conventional treatment of ulcerative colitis has been shown to be associated with improved rates of remission and improved maintenance of remission. [10] Some Bifidobacterium strains are considered as important probiotics and used in the food industry. Different species and/or strains of bifidobacteria may exert a range of beneficial health effects, including the regulation of intestinal microbial homeostasis, the inhibition of pathogens and harmful bacteria that colonize and/or infect the gut mucosa, the modulation of local and systemic immune responses, the repression of procarcinogenic enzymatic activities within the microbiota, the production of vitamins, and the bioconversion of a number of dietary compounds into bioactive molecules. [3] Bifidobacteria improve the gut mucosal barrier and lower levels of lipopolysaccharide in the intestine. [11]

Bifidobacteria may also improve abdominal pain in patients with irritable bowel syndrome (IBS) though studies to date have been inconclusive. [12]

Naturally occurring Bifidobacterium spp. may discourage the growth of Gram-negative pathogens in infants. [13]

A mother's milk contains high concentrations of lactose and lower quantities of phosphate (pH buffer). Therefore, when mother's milk is fermented by lactic acid bacteria (including bifidobacteria) in the infant's gastrointestinal tract, the pH may be reduced, making it more difficult for Gram-negative bacteria to grow.[ citation needed ]

Bifidobacteria and the infant gut

The human infant gut is relatively sterile up until birth, where it takes up bacteria from its surrounding environment and its mother. [14] The microbiota that makes up the infant gut differs from the adult gut. An infant reaches the adult stage of their microbiome at around three years of age, when their microbiome diversity increases, stabilizes, and the infant switches over to solid foods. Breast-fed infants are colonized earlier by Bifidobacterium when compared to babies that are primarily formula-fed. [15] Bifidobacterium is the most common bacteria in the infant gut microbiome. [16] There is more variability in genotypes over time in infants, making them less stable compared to the adult Bifidobacterium. Infants and children under three years old show low diversity in microbiome bacteria, but more diversity between individuals when compared to adults. [17] Reduction of Bifidobacterium and increase in diversity of the infant gut microbiome occurs with less breast-milk intake and increase of solid food intake. Mammalian milk all contain oligosaccharides showing natural selection [ clarification needed ]. Human milk oligosaccharides are not digested by enzymes and remain whole through the digestive tract before being broken down in the colon by microbiota. Bifidobacterium species genomes of B. longum, B. bifidum, B. breve contain genes that can hydrolyze some of the human milk oligosaccharides and these are found in higher numbers in infants that are breast-fed. Glycans that are produced by the humans are converted into food and energy for the B. bifidum. showing an example of coevolution. [18]

Species

The genus Bifidobacterium comprises the following species: [19]

See also

Related Research Articles

<span class="mw-page-title-main">Human microbiome</span> Microorganisms in or on human skin and biofluids

The human microbiome is the aggregate of all microbiota that reside on or within human tissues and biofluids along with the corresponding anatomical sites in which they reside, including the gastrointestinal tract, skin, mammary glands, seminal fluid, uterus, ovarian follicles, lung, saliva, oral mucosa, conjunctiva, and the biliary tract. Types of human microbiota include bacteria, archaea, fungi, protists, and viruses. Though micro-animals can also live on the human body, they are typically excluded from this definition. In the context of genomics, the term human microbiome is sometimes used to refer to the collective genomes of resident microorganisms; however, the term human metagenome has the same meaning.

<span class="mw-page-title-main">Actinomycetota</span> Phylum of bacteria

The Actinomycetota are a diverse phylum of Gram-positive bacteria with high GC content. They can be terrestrial or aquatic. They are of great importance to land flora because of their contributions to soil systems. In soil they help to decompose the organic matter of dead organisms so the molecules can be taken up anew by plants. While this role is also played by fungi, Actinomycetota are much smaller and likely do not occupy the same ecological niche. In this role the colonies often grow extensive mycelia, like a fungus would, and the name of an important order of the phylum, Actinomycetales, reflects that they were long believed to be fungi. Some soil actinomycetota live symbiotically with the plants whose roots pervade the soil, fixing nitrogen for the plants in exchange for access to some of the plant's saccharides. Other species, such as many members of the genus Mycobacterium, are important pathogens.

<span class="mw-page-title-main">Probiotic</span> Microorganisms said to provide health benefits when consumed

Probiotics are live microorganisms promoted with claims that they provide health benefits when consumed, generally by improving or restoring the gut microbiota. Probiotics are considered generally safe to consume, but may cause bacteria-host interactions and unwanted side effects in rare cases. There is some evidence that probiotics are beneficial for some conditions, such as helping to ease some symptoms of irritable bowel syndrome (IBS). However, many claimed health benefits, such as treating eczema, lack substantial scientific support.

<i>Lactobacillus acidophilus</i> Species of bacterium

Lactobacillus acidophilus is a rod-shaped, Gram-positive, homofermentative, anaerobic microbe first isolated from infant feces in the year 1900. The species is commonly found in humans, specifically the gastrointestinal tract and oral cavity as well as some speciality fermented foods such as fermented milk or yogurt, though it is not the most common species for this. The species most readily grows at low pH levels, and has an optimum growth temperature of 37 °C. Certain strains of L. acidophilus show strong probiotic effects, and are commercially used in dairy production. The genome of L. acidophilus has been sequenced.

Prebiotics are compounds in food that foster growth or activity of beneficial microorganisms such as bacteria and fungi. The most common environment considered is the gastrointestinal tract, where prebiotics can alter the composition of organisms in the gut microbiome.

<span class="mw-page-title-main">Gut microbiota</span> Community of microorganisms in the gut

Gut microbiota, gut microbiome, or gut flora are the microorganisms, including bacteria, archaea, fungi, and viruses, that live in the digestive tracts of animals. The gastrointestinal metagenome is the aggregate of all the genomes of the gut microbiota. The gut is the main location of the human microbiome. The gut microbiota has broad impacts, including effects on colonization, resistance to pathogens, maintaining the intestinal epithelium, metabolizing dietary and pharmaceutical compounds, controlling immune function, and even behavior through the gut–brain axis.

<i>Bifidobacterium animalis</i> Species of bacterium

Bifidobacterium animalis is a gram-positive, anaerobic, rod-shaped bacterium of the Bifidobacterium genus which can be found in the large intestines of most mammals, including humans.

A bifidus factor is a compound that specifically enhances the growth of bifidobacteria in either a product or in the intestines of humans and/or animals. Several products have been marketed as bifidogenic factors, such as several prebiotics and methyl-N-acetyl D-glucosamine in human milk.

Natural growth promoters (NGPs) are feed additives for farm animals.

Synbiotics refer to food ingredients or dietary supplements combining probiotics and prebiotics in a form of synergism, hence synbiotics. The synbiotic concept was first introduced as "mixtures of probiotics and prebiotics that beneficially affect the host by improving the survival and implantation of live microbial dietary supplements in the gastrointestinal tract, by selectively stimulating the growth and/or by activating the metabolism of one or a limited number of health-promoting bacteria, thus improving host welfare". As of 2018, the research on this concept is preliminary, with no high-quality evidence from clinical research that such benefits exist.

<span class="mw-page-title-main">Galactooligosaccharide</span> Class of prebiotics

Galactooligosaccharides (GOS), also known as oligogalactosyllactose, oligogalactose, oligolactose or transgalactooligosaccharides (TOS), belong to the group of prebiotics. Prebiotics are defined as non-digestible food ingredients that beneficially affect the host by stimulating the growth and/or activity of beneficial bacteria in the colon. GOS occurs in commercially available products such as food for both infants and adults.

<i>Bifidobacterium longum</i> Species of bacterium

Bifidobacterium longum is a Gram-positive, catalase-negative, rod-shaped bacterium present in the human gastrointestinal tract and one of the 32 species that belong to the genus Bifidobacterium. It is a microaerotolerant anaerobe and considered to be one of the earliest colonizers of the gastrointestinal tract of infants. When grown on general anaerobic medium, B. longum forms white, glossy colonies with a convex shape. B. longum is one of the most common bifidobacteria present in the gastrointestinal tracts of both children and adults. B. longum is non-pathogenic, is often added to food products, and its production of lactic acid is believed to prevent growth of pathogenic organisms.

Bacteriotherapy is the purposeful use of bacteria or their products in treating an illness. Forms of bacteriotherapy include the use of probiotics, microorganisms that provide health benefits when consumed; fecal matter transplants (FMT) /intestinal microbiota transplant (IMT), the transfer of gut microorganisms from the fecal matter of healthy donors to recipient patients to restore microbiota; or synbiotics which combine prebiotics, indigestible ingredients that promote growth of beneficial microorganisms, and probiotics. Through these methods, the gut microbiota, the community of 300-500 microorganism species that live in the digestive tract of animals aiding in digestion, energy storage, immune function and protection against pathogens, can be recolonized with favorable bacteria, which in turn has therapeutic effects.

<i>Bifidobacterium bifidum</i> Species of bacterium

Bifidobacterium bifidum is a bacterial species of the genus Bifidobacterium. B. bifidum is one of the most common probiotic bacteria that can be found in the body of mammals, including humans.

Microbiota-accessible carbohydrates (MACs) are carbohydrates that are resistant to digestion by a host's metabolism, and are made available for gut microbes, as prebiotics, to ferment or metabolize into beneficial compounds, such as short chain fatty acids. The term, ‘‘microbiota-accessible carbohydrate’’ contributes to a conceptual framework for investigating and discussing the amount of metabolic activity that a specific food or carbohydrate can contribute to a host's microbiota.

Bifidobacterium breve is a bacterial species of the genus Bifidobacterium which has probiotic properties. Bifidobacteria are a type of bacteria that live symbiotically in the intestines of humans. They have been used to treat a number of conditions including constipation, diarrhea, irritable bowel syndrome and even the cold and flu. Some of these uses have been backed up by scientific research, but others have not. B. breve is a gram positive, anaerobic, rod shaped organism that is non motile and forms branches with its neighbors.

Human milk oligosaccharides (HMOs), also known as human milk glycans, are short polymers of simple sugars that can be found in high concentrations in human breast milk. Human milk oligosaccharides promote the development of the immune system, can reduce the risk of pathogen infections and improve brain development and cognition. The HMO profile of human breast milk shapes the gut microbiota of the infant by selectively stimulating bifidobacteria and other bacteria.

<span class="mw-page-title-main">Human milk microbiome</span> Community of microorganisms in human milk

The human milk microbiota, also known as human milk probiotics (HMP), encompasses the microbiota–the community of microorganisms–present within the human mammary glands and breast milk. Contrary to the traditional belief that human breast milk is sterile, advancements in both microbial culture and culture-independent methods have confirmed that human milk harbors diverse communities of bacteria. These communities are distinct in composition from other microbial populations found within the human body which constitute the human microbiome.

Lacto-<i>N</i>-tetraose Chemical compound

Lacto-N-tetraose is a complex sugar found in human milk. It is one of the few characterized human milk oligosaccharides (HMOs) and is enzymatically synthesized from the substrate lactose. It is biologically relevant in the early development of the infant gut flora.

Bifidobacterium adolescentis is an anaerobic species of bacteria found in the gastrointestinal tracts of humans and other primates. It is one of the most abundant and prevalent Bifidobacterium species detected in human populations, especially in adults.

References

  1. Orla-Jensen S. (1924). "Classification des bactéries lactiques" [Classification of the lactic acid bacteria]. Le Lait. 4 (36): 468–474. doi: 10.1051/lait:19243627 .
  2. Schell MA, Karmirantzou M, Snel B, Vilanova D, Berger B, Pessi G, Zwahlen MC, Desiere F, Bork P, Delley M, Pridmore RD, Arigoni F (October 2002). "The genome sequence of Bifidobacterium longum reflects its adaptation to the human gastrointestinal tract". Proceedings of the National Academy of Sciences of the United States of America. 99 (22): 14422–7. Bibcode:2002PNAS...9914422S. doi: 10.1073/pnas.212527599 . PMC   137899 . PMID   12381787.
  3. 1 2 3 Mayo B, van Sinderen D, eds. (2010). Bifidobacteria: Genomics and Molecular Aspects. Caister Academic Press. ISBN   978-1-904455-68-4.[ page needed ]
  4. Albert, Arianne Y. K.; Chaban, Bonnie; Wagner, Emily C.; Schellenberg, John J.; Links, Matthew G.; Schalkwyk, Julie van; Reid, Gregor; Hemmingsen, Sean M.; Hill, Janet E.; Money, Deborah; Group, VOGUE Research (12 August 2015). "A Study of the Vaginal Microbiome in Healthy Canadian Women Utilizing cpn60-Based Molecular Profiling Reveals Distinct Gardnerella Subgroup Community State Types". PLOS ONE. 10 (8): e0135620. Bibcode:2015PLoSO..1035620A. doi: 10.1371/journal.pone.0135620 . PMC   4534464 . PMID   26266808.
  5. 1 2 "Potential of probiotics as biotherapeutic agents targeting the innate immune system" (PDF). African Journal of Biotechnology. February 2005.
  6. "Probiotics: 100 years (1907–2007) after Elie Metchnikoff's Observation" (PDF). Communicating Current Research and Educational Topics and Trends in Applied Microbiology. February 2007. Archived from the original (PDF) on 2012-10-04.
  7. "Pioneers of Probiotics". European Probiotic Association. February 2012. Archived from the original on 2013-07-22. Retrieved 2013-07-01.
  8. Sonomoto K, Yokota A, eds. (2011). Lactic Acid Bacteria and Bifidobacteria: Current Progress in Advanced Research. Caister Academic Press. ISBN   978-1-904455-82-0.[ page needed ]
  9. 1 2 Milani C, Turroni F, Duranti S, Lugli GA, Mancabelli L, Ferrario C, van Sinderen D, Ventura M (February 2016). "Genomics of the Genus Bifidobacterium Reveals Species-Specific Adaptation to the Glycan-Rich Gut Environment". Applied and Environmental Microbiology. 82 (4): 980–991. Bibcode:2016ApEnM..82..980M. doi:10.1128/AEM.03500-15. PMC   4751850 . PMID   26590291.
  10. Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW (9 December 2014). "Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease". Clinical and Experimental Gastroenterology. 7: 473–87. doi: 10.2147/CEG.S27530 . PMC   4266241 . PMID   25525379.
  11. Pinzone MR, Celesia BM, Di Rosa M, Cacopardo B, Nunnari G (2012). "Microbial translocation in chronic liver diseases". International Journal of Microbiology. 2012: 694629. doi: 10.1155/2012/694629 . PMC   3405644 . PMID   22848224.
  12. Pratt, Charlotte; Campbell, Matthew D. (2019-11-18). "The Effect of Bifidobacterium on Reducing Symptomatic Abdominal Pain in Patients with Irritable Bowel Syndrome: A Systematic Review". Probiotics and Antimicrobial Proteins. 12 (3): 834–839. doi: 10.1007/s12602-019-09609-7 . ISSN   1867-1306. PMC   7456408 . PMID   31741311.
  13. Liévin V, Peiffer I, Hudault S, Rochat F, Brassart D, Neeser JR, Servin AL (November 2000). "Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity". Gut. 47 (5): 646–52. doi:10.1136/gut.47.5.646. PMC   1728100 . PMID   11034580.
  14. Pham VT, Lacroix C, Braegger CP, Chassard C (July 2016). "Early colonization of functional groups of microbes in the infant gut". Environmental Microbiology. 18 (7): 2246–58. Bibcode:2016EnvMi..18.2246P. doi:10.1111/1462-2920.13316. PMID   27059115.
  15. Bourlieu C, Bouzerzour K, FerretBernard S, Bourgot CL, Chever S, Menard O, Deglaire A, Cuinet I, Ruyet PL, Bonhomme C, Dupont D (2015). "Infant formula interface and fat source impact on neonatal digestion and gut microbiota". European Journal of Lipid Science and Technology. 117 (10): 1500–1512. doi:10.1002/ejlt.201500025. ISSN   1438-9312.
  16. Turroni F, Peano C, Pass DA, Foroni E, Severgnini M, Claesson MJ, Kerr C, Hourihane J, Murray D, Fuligni F, Gueimonde M, Margolles A, De Bellis G, O'Toole PW, van Sinderen D, Marchesi JR, Ventura M (2012-05-11). "Diversity of bifidobacteria within the infant gut microbiota". PLOS ONE. 7 (5): e36957. Bibcode:2012PLoSO...736957T. doi: 10.1371/journal.pone.0036957 . PMC   3350489 . PMID   22606315.
  17. Matamoros S, Gras-Leguen C, Le Vacon F, Potel G, de La Cochetiere MF (April 2013). "Development of intestinal microbiota in infants and its impact on health". Trends in Microbiology. 21 (4): 167–73. doi:10.1016/j.tim.2012.12.001. PMID   23332725.
  18. Turroni F, Milani C, Duranti S, Ferrario C, Lugli GA, Mancabelli L, van Sinderen D, Ventura M (January 2018). "Bifidobacteria and the infant gut: an example of co-evolution and natural selection". Cellular and Molecular Life Sciences. 75 (1): 103–118. doi:10.1007/s00018-017-2672-0. PMC   11105234 . PMID   28983638. S2CID   24103287.
  19. Euzéby JP, Parte AC. "Actinomycetaceae". List of Prokaryotic names with Standing in Nomenclature (LPSN). Retrieved June 17, 2021.